Diligent Design Enables Antibody-ASO Conjugates with Optimal Pharmacokinetic Properties-Reference-Cited by-同舟云学术

Diligent Design Enables Antibody-ASO Conjugates with Optimal Pharmacokinetic Properties

Published:2023-11-02 Issue:11 Volume:34 Page:2096-2111
ISSN:1043-1802
Container-title:Bioconjugate Chemistry
language:en
Short-container-title:Bioconjugate Chem.

Author:

Sela Tatjana¹²^ORCID,Mansø Mads³,Siegel Michel⁴^ORCID,Marban-Doran Céline⁴,Ducret Axel⁴^ORCID,Niewöhner Jens¹,Ravn Jacob³,Martin Rainer E.⁴^ORCID,Sommer Annika¹,Lohmann Sabine¹,Krippendorff Ben-Fillippo⁴,Ladefoged Mette³,Indlekofer Annette¹,Quaiser Tom¹,Bueddefeld Florian¹,Koller Erich⁴,Mohamed Mohamed Y.⁵,Oelschlaegel Tobias⁵,Gothelf Kurt V.⁶^ORCID,Hofer Kerstin¹,Schumacher Felix F.⁴^ORCID

Affiliation:

1. Roche Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Roche Diagnostics GmbH, Nonnenwald 2, Penzberg 82377, Germany

2. Department of Biochemistry, Ludwig-Maximilians-Universität, Munich 80539, Germany

3. Roche Pharma Research and Early Development (pRED), Roche Innovation Center Copenhagen, F. Hoffmann-La Roche Ltd., Fremtidsvej 3, Hørsholm 2970, Denmark

4. Roche Pharma Research and Early Development (pRED), Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, Basel 4070, Switzerland

5. Roche Diagnostics GmbH, Nonnenwald 2, Penzberg 82377, Germany

6. Department of Chemistry and Interdisciplinary Nanoscience Centre (iNANO), Aarhus University, Aarhus 8000, Central Denmark Region, Denmark

Publisher

American Chemical Society (ACS)

Subject

Organic Chemistry,Pharmaceutical Science,Pharmacology,Biomedical Engineering,Bioengineering,Biotechnology

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.bioconjchem.3c00393

Reference84 articles.

1. A randomized controlled clinical trial of intravitreous fomivirsen for treatment of newly diagnosed peripheral cytomegalovirus retinitis in patients with aids11InternetAdvance publication at ajo.com Feb 8, 2002.Financial disclosures and conflict of interest statements are listed at the end of the article.Reprint requests to René Lanz, PhD, Novartis Ophthalmics AG, Grenzstrasse 10, CH-8180 Bülach, Switzerland; fax: (41) 1-862-0762; e-mail: rene.lanz@pharma.novartis.comCorrespondence to Stephen L. Hutcherson, MBA, Cyclix Ltd. LLC, 11851 Rexmoor Drive, Richmond, VA 23236; fax: (804) 897-9544; e-mail: cyclix@comcast.net

2. Mipomersen preferentially reduces small low-density lipoprotein particle number in patients with hypercholesterolemia

3. Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy

4. Eteplirsen for the treatment of Duchenne muscular dystrophy

5. Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis